



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	International Blood Research & Reviews
Manuscript Number:	Ms IBRR 36037
Title of the Manuscript:	Profile of CD4, Tumor necrosis factor alpha, Hematological parameters and prevalence of hematological cytopenia in HIV seropositive patients on Anti-retroviral therapy in university of port Harcourt teaching hospital.
New Title of the Manuscript:	Immunological and Hematological profile of HIV patients on Anti-retroviral therapy in Port Harcourt, Rivers State, Nigeria
Type of Article:	Original Research Article

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<ol style="list-style-type: none"> 1. There should be prior definition of abbreviations before their use in the manuscript. For example AR??? 2. Is "reduced CD4" the consequence of CD4<200? CD4<200 is by itself reduced CD4 level. (Can something be a consequence of itself???) 3. Your sample size calculation should be based on your surrogate (primary) marker which is? 4. Authors should make manuscript "reader-friendly" by meticulously revising it sentence-by-sentence. Emphasis should be placed on transitions, punctuation marks and their right placements in sentences because some flaws in the manuscript are a consequence of these inadequacies. They should also do a thorough word check for some minor spelling errors. 5. Authors should be watchful against the persistent use of "makers" in the place of "markers" when referring to the study parameters. 6. Frequencies and percentages in the table of demographic data should be accompanied with their respective formulas; readers need all these details. 	<p>Corrected.</p> <p>"CD4 less than 200" was used as a factor to categorize our HIV patients.</p> <p>Correction has been effected</p> <p>Correction has been effected</p> <p>Makers have been corrected to markers.</p> <p>Formula has been inserted.</p>